Key result
Genetic testing identifies pathogenic variants in 29% of patients with suspected genetic heart disease.
Why the study?
Current practices across cardiac genetics clinics in Australia had not been established in a nationwide audit.
Observational (n=536)
Yes
This national audit provides baseline data on the models of care and diagnostic yield (29%) of genetic testing for suspected genetic heart diseases in Australia.
Answers are grounded in this paper and cite their sources.
Supplies baseline Australian data on genetic testing models and yield; leaves open optimal strategies and outcome impacts.
BACKGROUND: This sub-study of the Australian Genomics Cardiovascular Genetic Disorders Flagship sought to conduct the first nation-wide audit in Australia to establish the current practices across cardiac genetics clinics. METHOD: An audit of records of patients with a suspected genetic heart disease (cardiomyopathy, primary arrhythmia, autosomal dominant congenital heart disease) who had a cardiac genetics consultation between 1st January 2016 and 31 July 2018 and were offered a diagnostic genetic test. RESULTS: This audit included 536 records at multidisciplinary cardiac genetics clinics from 11 public tertiary hospitals across five Australian states. Most genetic consultations occurred in a clinic setting (90%), followed by inpatient (6%) and Telehealth (4%). Queensland had the highest proportion of Telehealth consultations (9% of state total). Sixty-six percent of patients had a clinical diagnosis of a cardiomyopathy, 28% a primary arrhythmia, and 0.7% congenital heart disease. The reason for diagnosis was most commonly as a result of investigations of symptoms (73%). Most patients were referred by a cardiologist (85%), followed by a general practitioner (9%) and most genetic tests were funded by the state Genetic Health Service (73%). Nationally, 29% of genetic tests identified a pathogenic or likely pathogenic gene variant; 32% of cardiomyopathies, 26% of primary arrhythmia syndromes, and 25% of congenital heart disease. CONCLUSION: We provide important information describing the current models of care for genetic heart diseases throughout Australia. These baseline data will inform the implementation and impact of whole genome sequencing in the Australian healthcare landscape.
No takes yet. Share an insight, caveat, or question.
Austin et al. (2021) conducted an observational in Suspected genetic heart disease (n=536). Diagnostic genetic testing was evaluated on Identification of a pathogenic or likely pathogenic gene variant. A national clinical audit of 536 patients with suspected genetic heart disease found that diagnostic genetic testing identified a pathogenic or likely pathogenic gene variant in 29% of cases.
Synapse has enriched 10 related papers. Consider them for comparative context: